Restoring Balance

At Aldeyra, we’re a pioneer in the development of medicines to improve the lives of patients with immune-mediated diseases. Our pipeline of drug candidates is focused on inhibiting inflammatory cells linked to ocular and systemic conditions not adequately addressed by current treatments. By inventing, developing and commercializing these next-generation therapies, we have one goal: to help patients lead healthier lives.

Our Mission

Patients Like Daniele Are the Reason We’re Developing Next-generation Medicines

With investigational therapies in Phase 3 trials for dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopathy (PVR), we continue to advance toward our goal of bringing to market novel medicines for immune-mediated conditions not adequately addressed by current treatments.
Learn More
Our Science

Restoring Balance Utilizing Novel Mechanisms of Action

An estimated 7% of western society suffers from some form of immune-mediated disease. At Aldeyra, we are building a proprietary pipeline focused on three distinct mechanisms of action: Reactive Aldehyde Species (RASP) inhibition, Dihydrofolate Reductase (DHFR) inhibition, and Chaperome (CHP) inhibitors to target immune-mediated ocular diseases and select systemic conditions.
Learn More
Scientist placing a sample under a microscope

Therapeutic Focus

Targeting Immune-Mediated Diseases with High Unmet Need

Brown eye with eye dropper

Ocular Diseases

We’re developing therapies for the treatment of dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopathy.

Read More About Ocular Disease Treatment

Woman holding healthcare provider’s hand

Systemic Diseases

We’re developing product candidates that can be administered orally or by injection to treat systemic disease.

Read More About Systemic Disease Treatment